A new class of gene therapies that correct dysfunctional messenger RNA
Correct the message
Change a life
A new class of gene therapies that correct dysfunctional messenger RNA
A new advance in genetic medicines
Locanabio is pioneering a new class of targeted therapies that specifically corrects dysfunctional RNA, the root cause of many devastating genetic diseases. By combining the specificity of RNA-binding proteins with the durable effect of a one-time gene therapy, we can address the underlying RNA defects in patients suffering from rare neuromuscular, neurodegenerative and retinal diseases.
Powerful Platform
Learn how our science targets the RNA dysfunction of severe diseases
Partnership Opportunities
Build a valuable partnership with us—adjusting our platform to advance your programs
Inspiring Careers
Explore exciting careers at a company committed to making a positive difference in lives